Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015 (2015), Article ID 539787, 11 pages
http://dx.doi.org/10.1155/2015/539787
Research Article

Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction

1Department of Pathology, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands
2Department of Nephrology and Hypertension, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands
3Department of Internal Medicine, University Medical Center Groningen, 9700 RB Groningen, Netherlands
4HaemoScan, 9723 JC Groningen, Netherlands
5Department of Pathology, Academic Medical Center, 1105 AZ Amsterdam, Netherlands
6Steno Diabetes Center, 2820 Gentofte, Denmark
7Department of Nephrology, Radboud University Nijmegen Medical Centre, 6525 GA Nijmegen, Netherlands
8Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, Netherlands

Received 17 February 2015; Revised 27 May 2015; Accepted 3 June 2015

Academic Editor: Amandine Gautier-Stein

Copyright © 2015 Karin G. F. Gerritsen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md, USA, 2013.
  2. S. G. Adler, S.-W. Kang, S. Feld et al., “Glomerular mRNAS in human type 1 diabetes: biochemical evidence for microalbuminuria as a manifestation of diabetic nephropathy,” Kidney International, vol. 60, no. 6, pp. 2330–2336, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Ito, J. Aten, R. J. Bende et al., “Expression of connective tissue growth factor in human renal fibrosis,” Kidney International, vol. 53, no. 4, pp. 853–861, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. R. M. Mason, “Connective tissue growth factor (CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it?” Journal of Cell Communication and Signaling, vol. 3, no. 2, pp. 95–104, 2009. View at Publisher · View at Google Scholar
  5. T. Q. Nguyen, P. Roestenberg, F. A. van Nieuwenhoven et al., “CTGF inhibits BMP-7 signaling in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 19, no. 11, pp. 2098–2107, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Turk, J. W. Leeuwis, J. Gray et al., “BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression,” Journal of Histochemistry and Cytochemistry, vol. 57, no. 7, pp. 623–631, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. N. A. Wahab, L. Schaefer, B. S. Weston et al., “Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli,” Diabetologia, vol. 48, no. 12, pp. 2650–2660, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. L. R. James, C. Le, H. Doherty, H.-S. Kim, and N. Maeda, “Connective tissue growth factor (CTGF) expression modulates response to high glucose,” PLoS ONE, vol. 8, no. 8, Article ID e70441, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. S. G. Adler, S. Schwartz, M. E. Williams et al., “Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 8, pp. 1420–1428, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Yokoi, M. Mukoyama, K. Mori et al., “Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice,” Kidney International, vol. 73, no. 4, pp. 446–455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Guha, Z.-G. Xu, D. Tung, L. Lanting, and R. Natarajan, “Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes,” The FASEB Journal, vol. 21, no. 12, pp. 3355–3368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Andersen, F. A. van Nieuwenhoven, L. Tarnow et al., “Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy,” Kidney International, vol. 67, no. 6, pp. 2325–2329, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. R. E. Gilbert, A. Akdeniz, S. Weitz et al., “Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy,” Diabetes Care, vol. 26, no. 9, pp. 2632–2636, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Q. Nguyen, L. Tarnow, S. Andersen et al., “Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy,” Diabetes Care, vol. 29, no. 1, pp. 83–88, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. F. W. K. Tam, B. L. Riser, K. Meeran, J. Rambow, C. D. Pusey, and A. H. Frankel, “Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy,” Cytokine, vol. 47, no. 1, pp. 37–42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. K. G. F. Gerritsen, H. P. Peters, T. Q. Nguyen et al., “Renal proximal tubular dysfunction is a major determinant of urinary connective tissue growth factor excretion,” The American Journal of Physiology—Renal Physiology, vol. 298, no. 6, pp. F1457–F1464, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. A. Jaffa, W. R. Usinger, M. B. McHenry et al., “Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 5, pp. 1893–1900, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. O. Miyazaki, S. Kurashita, I. Fukamachi, K. Endo, P.-S. Ng, and K. Takehara, “Subtraction method for determination of N-terminal connective tissue growth factor,” Annals of Clinical Biochemistry, vol. 47, no. 3, pp. 205–211, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Roestenberg, F. A. van Nieuwenhoven, L. Wieten et al., “Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy,” Diabetes Care, vol. 27, no. 5, pp. 1164–1170, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, “A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation,” Annals of Internal Medicine, vol. 130, no. 6, pp. 461–470, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Meijer, W. E. Boertien, F. L. Nauta et al., “Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis,” American Journal of Kidney Diseases, vol. 56, no. 5, pp. 883–895, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. T. D. Lockwood and H. B. Bosmann, “The use of urinary N-acetyl-beta-glucosaminidase in human renal toxicology. I. Partial biochemical characterization and excretion in humans and release from the isolated perfused rat kidney,” Toxicology and Applied Pharmacology, vol. 49, no. 2, pp. 323–336, 1979. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Ito, R. Goldschmeding, H. Kasuga et al., “Expression patterns of connective tissue growth factor and of TGF-β isoforms during glomerular injury recapitulate glomerulogenesis,” American Journal of Physiology—Renal Physiology, vol. 299, no. 3, pp. F545–F558, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar
  25. M. T. Schram, N. Chaturvedi, C. G. Schalkwijk, J. H. Fuller, and C. D. A. Stehouwer, “Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study,” Diabetologia, vol. 48, no. 2, pp. 370–378, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Pietravalle, S. Morano, G. Cristina et al., “Charge selectivity of proteinuria in type I diabetes explored by Ig subclass clearance,” Diabetes, vol. 40, no. 12, pp. 1685–1690, 1991. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Penders and J. R. Delanghe, “Alpha 1-microglobulin: clinical laboratory aspects and applications,” Clinica Chimica Acta, vol. 346, no. 2, pp. 107–118, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. M. A. G. J. ten Dam, A. J. W. Branten, I. S. Klasen, and J. F. M. Wetzels, “The gelatin-derived plasma substitute gelofusine causes low-molecular-weight proteinuria by decreasing tubular protein reabsorption,” Journal of Critical Care, vol. 16, no. 3, pp. 115–120, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Waanders, G. Navis, and H. van Goor, “Urinary tubular biomarkers of kidney damage: potential value in clinical practice,” The American Journal of Kidney Diseases, vol. 55, no. 5, pp. 813–816, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Waanders, M. M. van Timmeren, C. A. Stegeman, S. J. L. Bakker, and H. van Goor, “Kidney injury molecule-1 in renal disease,” Journal of Pathology, vol. 220, no. 1, pp. 7–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. J. M. Hofstra, J. K. J. Deegens, E. J. Steenbergen, and J. F. M. Wetzels, “Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy,” Nephrology Dialysis Transplantation, vol. 23, no. 10, pp. 3160–3165, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. R. G. H. J. Maatman, T. H. M. S. M. Van Kuppervelt, and J. H. Veerkamp, “Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization,” Biochemical Journal, vol. 273, no. 3, pp. 759–766, 1991. View at Google Scholar · View at Scopus
  33. S. E. Thomson, S. V. McLennan, P. D. Kirwan et al., “Renal connective tissue growth factor correlates with glomerular basement membrane thickness and prospective albuminuria in a non-human primate model of diabetes: possible predictive marker for incipient diabetic nephropathy,” Journal of Diabetes and Its Complications, vol. 22, no. 4, pp. 284–294, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Wang, M. DeNichilo, C. Brubaker, and R. Hirschberg, “Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy,” Kidney International, vol. 60, no. 1, pp. 96–105, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Kobayashi, H. Okada, T. Inoue, Y. Kanno, and H. Suzuki, “Tubular expression of connective tissue growth factor correlates with interstitial fibrosis in type 2 diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 21, no. 2, pp. 548–549, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. R. E. Gilbert and M. E. Cooper, “The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?” Kidney International, vol. 56, no. 5, pp. 1627–1637, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. C. J. Magri and S. Fava, “The role of tubular injury in diabetic nephropathy,” European Journal of Internal Medicine, vol. 20, no. 6, pp. 551–555, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. E. F. O. Kern, P. Erhard, W. Sun, S. Genuth, and M. F. Weiss, “Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT),” American Journal of Kidney Diseases, vol. 55, no. 5, pp. 824–834, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. S. E. Nielsen, T. Sugaya, P. Hovind, T. Baba, H.-H. Parving, and P. Rossing, “Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients,” Diabetes Care, vol. 33, no. 6, pp. 1320–1324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. S. E. Nielsen, K. J. Schjoedt, A. S. Astrup et al., “Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril,” Diabetic Medicine, vol. 27, no. 10, pp. 1144–1150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. S. E. Nielsen, T. Sugaya, L. Tarnow et al., “Tubular and glomerular injury in diabetes and the impact of ACE inhibition,” Diabetes Care, vol. 32, no. 9, pp. 1684–1688, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. N. A. Wahab, B. S. Weston, and R. M. Mason, “Modulation of the TGFβ/Smad signaling pathway in mesangial cells by CTGF/CCN2,” Experimental Cell Research, vol. 307, no. 2, pp. 305–314, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. Y.-C. Tay, Y. Wang, L. Kairaitis, G. K. Rangan, C. Zhang, and D. C. H. Harris, “Can murine diabetic nephropathy be separated from superimposed acute renal failure?” Kidney International, vol. 68, no. 1, pp. 391–398, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. B. L. Riser, M. Denichilo, P. Cortes et al., “Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis,” Journal of the American Society of Nephrology, vol. 11, no. 1, pp. 25–38, 2000. View at Google Scholar · View at Scopus
  45. S. M. Twigg, Z. Cao, S. V. McLennan et al., “Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine,” Endocrinology, vol. 143, no. 12, pp. 4907–4915, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Roestenberg, F. A. van Nieuwenhoven, J. A. Joles et al., “Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice,” The American Journal of Physiology—Renal Physiology, vol. 290, no. 6, pp. F1344–F1354, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Q. Nguyen, L. Tarnow, A. Jorsal et al., “Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy,” Diabetes Care, vol. 31, no. 6, pp. 1177–1182, 2008. View at Publisher · View at Google Scholar · View at Scopus